evipedia.aidev
← Back to Review

Audit: QRS - PEG-MGF for Health & Longevity of the ER frontmatter

Audit conducted on 02/07/2026 01:24 using AI4L / Opus 4.8

Iterations

Summary

Items Count
Total 91
Passed 87
Failed 0
N/A 4
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All content (benefits, risks, protocol, monitoring, gates) traces to the ER.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 QRS preserves “unproven”, “no human trials”, “Theoretical cancer-promotion”, “Speculative” matching ER caution.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Contraindications carried as hard stops; benefits kept speculative.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 Contraindications, interactions, benefits, and risks map to their ER sections without relabeling.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 QRS contains no PMIDs, citations, or expert names.
1.6 The QRS does not introduce new attributions. 🟢 No attributions introduced.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Cautious, evidence-focused tone matching the ER.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Meets tone requirements.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Presents information, not prescriptions.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 No directive medical advice; footer disclaims.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 Descriptive framing throughout.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person address.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Plain-language summaries used.
2.8 Information is presented in a concise and very compact manner 🟢 Compact card/table layout.
2.9 It DOES NOT address the reader directly 🟢 No direct address.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Framing targets risk-aware longevity readers.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Consistent with audience.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 Not general-population framing.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 Risk-forward weighting reflects the audience.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 No “anti-aging” usage.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢 Uses “Subcutaneous”, “injection”, “administration”.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All fixed headings/labels intact.
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All 57 expected data-qrs-var spans present.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 Untouched template spans unchanged.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” 🟢 No populated section required empty-state phrasing; unused tiers hidden.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 Protocol labels (Dose, Frequency, Timing) and tier labels match.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Labels faithful to ER.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji indicators in QRS body.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Content condensed to one-page budget.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Metadata comment at lines 2-14, first after doctype.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 YAML delimited by — at lines 3 and 13.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in HTML comment.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Only duration (contains colon) is quoted.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 er_filename: peg_mgf_2026-0702-0005_Opus_ER.md
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 qrs_prompt_version: 26.5.18
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 qrs_creation_date: 2026-0702-0005
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 qrs_creator_ai_nickname: Opus
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 “Opus” is single-word.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 qrs_creator_ai_fullname: Opus 4.8
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 “Opus 4.8” — nickname + version.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 qrs_filename: peg_mgf_2026-0702-0005_Opus_QRS.html
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Values trimmed; only duration quoted.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 “PEG-MGF for Health & Longevity - Quick Reference Sheet”.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 “PEG-MGF for Health & Longevity”.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 07/02/2026 (from 2026-0702).
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 “Opus 4.8”.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 Header contains only topic and standard subline.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Condenses the ER Conclusion faithfully.
7.2 [at_a_glance] is no longer than 60 words 🟢 55 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Each claim maps to a Conclusion passage.
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 No specialist acronyms; plain language.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial citations.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No statistics.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Derived from ER “Populations who should avoid PEG-MGF”.
8.2 [stop_items] represent the Contraindications from the ER 🟢 All 6 avoid-populations captured.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Each item is a <li>.
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Items concise; no trailing dash clauses.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Cancer parenthetical “(especially prostate, colorectal, endometrial, or bone)” preserved.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. 🟢 No ranking symbols; parentheticals already comma-separated.
8.7 If no [stop_items] are present the section is left empty N/A stop_items are present.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Derived from ER interaction bullets.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 4 interactions; OTC “none documented” bullet correctly omitted.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Each item is a <li>.
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Items concise; no trailing dash clauses.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Example drug parentheticals preserved (sulfonylureas, IGF-1 LR3, etc.).
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. 🟢 No ranking symbols carried through.
9.7 If no [caution_items] are present the section is left empty N/A caution_items are present.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 Derived from ER Therapeutic Protocol.
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Dose, Frequency, Timing.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A Three action sets are populated.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All three cells filled with ER-derived content.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 ER provides one time-to-effect aspect (subjective recovery, days to weeks); captured.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Single applicable aspect placed first.
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. 🟢 time_2 and time_3 set to display:none, empty.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 time_1 filled from ER Practical Considerations.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A ER provides time-to-effect information.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 Derived from ER Expected Benefits.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four variables present.
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Speculative list of five benefits kept concise.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheticals in benefits.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 high/medium/low set to display:none; only speculative populated.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 Derived from ER Potential Risks & Side Effects.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four variables populated.
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Each tier reduced to key fact.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 No parentheticals retained.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 All four tiers have ER content; none empty.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Derived from ER Monitoring Protocol table.
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All 6 markers (IGF-1, fasting glucose, HbA1c, PSA, hs-CRP, CBC) listed.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 “Baseline, at ~4–6 weeks, and every 3–6 months during any continued use”.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 Derived from ER qualitative markers list.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All 5 qualitative markers listed.

Issues 02/07/2026 01:24

Pass rate 100.00%. No issues found.